Species dependence of A3 adenosine receptor pharmacology and function
Zhan-Guo Gao,John A. Auchampach,Kenneth A. Jacobson
DOI: https://doi.org/10.1007/s11302-022-09910-1
2022-12-21
Purinergic Signalling
Abstract:Efforts to fully understand pharmacological differences between G protein-coupled receptor (GPCR) species homologues are generally not pursued in detail during the drug development process. To date, many GPCRs that have been successfully targeted are relatively well-conserved across species in amino acid sequence and display minimal variability of biological effects. However, the A 3 adenosine receptor (AR), an exciting drug target for a multitude of diseases associated with tissue injury, ischemia, and inflammation, displays as little as 70% sequence identity among mammalian species (e.g., rodent vs. primate) commonly used in drug development. Consequently, the pharmacological properties of synthetic A 3 AR ligands vary widely, not only in binding affinity, selectivity, and signaling efficacy, but to the extent that some function as agonists in some species and antagonists in others. Numerous heterocyclic antagonists that have nM affinity at the human A 3 AR are inactive or weakly active at the rat and mouse A 3 ARs. Positive allosteric modulators, including the imidazo [4,5-c]quinolin-4-amine derivative LUF6000, are only active at human and some larger animal species that have been evaluated (rabbit and dog), but not rodents. A 3 AR agonists evoke systemic degranulation of rodent, but not human mast cells. The rat A 3 AR undergoes desensitization faster than the human A 3 AR, but the human homologue can be completely re-sensitized and recycled back to the cell surface. Thus, comprehensive pharmacological evaluation and awareness of potential A 3 AR species differences are critical in studies to further understand the basic biological functions of this unique AR subtype. Recombinant A 3 ARs from eight different species have been pharmacologically characterized thus far. In this review, we describe in detail current knowledge of species differences in genetic identity, G protein-coupling, receptor regulation, and both orthosteric and allosteric A 3 AR pharmacology.
neurosciences